MedTrace Logo

Coenzyme Q10 as Adjunctive Therapy in Drug-Resistant Epilepsy

NCT07537283 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-04-17

No results posted yet for this study

Summary

This study evaluates the efficacy and safety of coenzyme Q10 supplementation as adjunctive therapy in patients with drug-resistant epilepsy.

Conditions

Interventions

DIETARY_SUPPLEMENT

coenzyme Q10

Coenzyme Q10 administered orally as an adjunct to baseline anti-seizure medications for 12 weeks.

DIETARY_SUPPLEMENT

Placebo

Matching placebo capsules administered orally once daily for 12 weeks.

Sponsors & Collaborators

  • National Cheng-Kung University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-07
Primary Completion
2023-09-28
Completion
2023-11-28

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07537283 on ClinicalTrials.gov